2022
DOI: 10.1097/qad.0000000000003192
|View full text |Cite
|
Sign up to set email alerts
|

Baseline HIV drug-resistance testing: 12 US jurisdictions, 2014–2019

Abstract: Objective:To understand recent patterns in reported baseline HIV drug-resistance testing over time in the United States.Design:Data from the National HIV Surveillance System for persons who were aged at least 13 years at the time of HIV diagnosis during 2014–2019 and resided in one of 12 US jurisdictions with high levels of reporting in 2014 and 2015.Methods:Among persons included in the analysis, we calculated the total proportion of HIV diagnoses occurring during 2014–2019 with a reported baseline sequence b… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

1
4
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(5 citation statements)
references
References 12 publications
1
4
0
Order By: Relevance
“…We did not detect any mutation of clinical interest against INSTI, which supports the continued use of INSTI in the country. None or low resistance levels to INSTIs were also observed in previous studies from sub-Saharan African regions, such as East African countries (0%) 26 , Ethiopia (0%) 27 , Nigeria (0%) 28 , Cameroon (1.4%) 29 , and South Africa (2.2%) 30 , as well as in America such as in Brazil (0%) 31 and the US (1.9%) 32 , or 2.3% in Europe as reported in the MeditRes which is a consortium that includes ART-naïve patients newly diagnosed in France, Greece, Italy, Portugal, and Spain during 2018–2021 33 . On the other hand, we detected accessory mutations (L74M, T97A, Q95K, and S153A) that have little effect unless they present with other major mutations (Fig.…”
Section: Discussionsupporting
confidence: 72%
“…We did not detect any mutation of clinical interest against INSTI, which supports the continued use of INSTI in the country. None or low resistance levels to INSTIs were also observed in previous studies from sub-Saharan African regions, such as East African countries (0%) 26 , Ethiopia (0%) 27 , Nigeria (0%) 28 , Cameroon (1.4%) 29 , and South Africa (2.2%) 30 , as well as in America such as in Brazil (0%) 31 and the US (1.9%) 32 , or 2.3% in Europe as reported in the MeditRes which is a consortium that includes ART-naïve patients newly diagnosed in France, Greece, Italy, Portugal, and Spain during 2018–2021 33 . On the other hand, we detected accessory mutations (L74M, T97A, Q95K, and S153A) that have little effect unless they present with other major mutations (Fig.…”
Section: Discussionsupporting
confidence: 72%
“…Within this context, Hugueley et al [7] report an analysis of baseline HIV drug resistance testing from the United States, published in this edition of AIDS . Between 2014 and 2019, approximately half of individuals newly diagnosed with HIV in select public health jurisdictions had baseline genotypic resistance testing that was collected within 90 days of diagnosis and was reported to the local jurisdiction.…”
mentioning
confidence: 99%
“…Prior to recommendations for routine baseline genotyping, laboratory testing for drug resistance monitoring in the United States was funded through public health mechanisms. Instead of a pressing need for expanded clinical resistance testing and reporting, as Hugueley et al [7] suggest, perhaps it is time for public health to resume targeted surveillance strategies and work towards broad validation and implementation of less costly laboratory methods (such as next-generation sequencing). Targeted surveillance may be sufficient to monitor for changing patterns of transmitted resistance mutations, though it would raise new challenges for cluster identification and response because current approaches rely on completeness of sequence data.…”
mentioning
confidence: 99%
See 2 more Smart Citations